Last reviewed · How we verify

PL2200 Aspirin Capsules — Competitive Intelligence Brief

PL2200 Aspirin Capsules (PL2200 Aspirin Capsules) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent (aspirin formulation). Area: Cardiovascular.

phase 3 Antiplatelet agent (aspirin formulation) Cyclooxygenase-1 (COX-1) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

PL2200 Aspirin Capsules (PL2200 Aspirin Capsules) — PLx Pharma. PL2200 is a modified-release aspirin formulation designed to reduce gastrointestinal irritation while maintaining antiplatelet efficacy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PL2200 Aspirin Capsules TARGET PL2200 Aspirin Capsules PLx Pharma phase 3 Antiplatelet agent (aspirin formulation) Cyclooxygenase-1 (COX-1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent (aspirin formulation) class)

  1. PLx Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PL2200 Aspirin Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/pl2200-aspirin-capsules. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: